|Articles|June 1, 2001

June 2001
Volume 7
Issue 6

Prevalence and Determinants of Osteoporosis Drug Prescription Among Patients with High Exposure to Glucocorticoid Drugs

Author(s)Bruce Ettinger, MD, Preeta Chidambaran, MD, Alice Pressman, MS

Download PDF: Prevalence and Determinants of Osteoporosis Drug Prescription Among Patients with High Exposure to Glucocorticoid Drugs

Articles in this issue

about 25 years ago

Article

Health Plan's Use of Asthma Quality Improvement Projects to Meet NCQA Accreditation Standards

about 25 years ago

Article

Does the HEDIS Asthma Measure Go Far Enough?

about 25 years ago

Article

Diagnosis and Care of Irritable Bowel Syndrome in a Community-Based Population

about 25 years ago

Article

Effect of Rofecoxib Therapy on Measures of Health-Related Quality of Life in Patients with Osteoarthritis

about 25 years ago

Article

Rheumatoid Arthritis: Guidelines for Emerging Therapies

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Prevalence and Determinants of Osteoporosis Drug Prescription Among Patients with High Exposure to Glucocorticoid Drugs

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO

GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

Childhood Influenza Vaccine Rates Decreased From 2017 to 2023